Financhill
Sell
38

HNSBF Quote, Financials, Valuation and Earnings

Last price:
$3.00
Seasonality move :
10.81%
Day range:
$3.00 - $3.00
52-week range:
$2.65 - $3.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.81x
P/B ratio:
--
Volume:
--
Avg. volume:
180
1-year change:
13.21%
Market cap:
$196.8M
Revenue:
$12.7M
EPS (TTM):
-$1.08

Analysts' Opinion

  • Consensus Rating
    Hansa Biopharma AB has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Downside
    According to analysts' consensus price target of --, Hansa Biopharma AB has an estimated downside of -- from its current price of $3.00.
  • Price Target Upside
    According to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $3.00.

Fair Value

  • According to the consensus of 0 analysts, Hansa Biopharma AB has -- downside to fair value with a price target of -- per share.

HNSBF vs. S&P 500

  • Over the past 5 trading days, Hansa Biopharma AB has overperformed the S&P 500 by 4.34% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Hansa Biopharma AB does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Hansa Biopharma AB has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Hansa Biopharma AB reported revenues of $4.7M.

Earnings Growth

  • Hansa Biopharma AB has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Hansa Biopharma AB reported earnings per share of -$0.15.
Enterprise value:
235.5M
EV / Invested capital:
--
Price / LTM sales:
9.81x
EV / EBIT:
--
EV / Revenue:
13.04x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.46x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$9.7M
Return On Assets:
-65.34%
Net Income Margin (TTM):
-345.05%
Return On Equity:
--
Return On Invested Capital:
-95.02%
Operating Margin:
-240.28%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $14.1M $10.8M $18.1M $2.1M $4.7M
Gross Profit $10.3M $6.1M $9.7M $573K $3.6M
Operating Income -$62.5M -$70.5M -$61M -$18.7M -$11.3M
EBITDA -$63.4M -$69M -$53.7M -$18.7M -$11.3M
Diluted EPS -$1.47 -$1.57 -$1.08 -$0.44 -$0.15
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $165.3M $117.8M $118.5M $93.8M $74M
Total Assets $170.3M $124.2M $124M $107.3M $93.3M
Current Liabilities $12.8M $13.3M $18.4M $27.2M $30.2M
Total Liabilities $21M $21.9M $93M $113M $125M
Total Equity $149.3M $102.3M $31M -$5.7M -$31.7M
Total Debt -- -- $68.3M $83.1M $93.5M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$51.4M -$66.7M -$68.1M -$16.9M -$15.3M
Cash From Investing $22.2M $623.8K $25.9K $1.7K -$300
Cash From Financing $68.8M $42M $33.4M -$158K $734K
Free Cash Flow -$51.4M -$67.1M -$68.1M -$16.9M -$15.3M
HNSBF
Sector
Market Cap
$196.8M
$48.9M
Price % of 52-Week High
82.19%
49.34%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
13.21%
-30.56%
Beta (5-Year)
0.486
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $2.92
200-day SMA
Sell
Level $3.03
Bollinger Bands (100)
Sell
Level 2.79 - 3.47
Chaikin Money Flow
Buy
Level 16.3K
20-day SMA
Buy
Level $2.86
Relative Strength Index (RSI14)
Sell
Level 46.87
ADX Line
Sell
Level 65.57
Williams %R
Sell
Level 0
50-day SMA
Sell
Level $3.30
MACD (12, 26)
Sell
Level -0.08
25-day Aroon Oscillator
Sell
Level -12
On Balance Volume
Neutral
Level 11.8K

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-5.4171)
Sell
CA Score (Annual)
Level (-4.3533)
Sell
Beneish M-Score (Annual)
Level (8.0141)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (7.382)
Sell
Piotroski F Score (Annual)
Level (2)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Stock Forecast FAQ

In the current month, HNSBF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HNSBF average analyst price target in the past 3 months is --.

  • Where Will Hansa Biopharma AB Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Hansa Biopharma AB share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About Hansa Biopharma AB?

    Analysts are divided on their view about Hansa Biopharma AB share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Hansa Biopharma AB is a Sell and believe this share price will rise from its current level to --.

  • What Is Hansa Biopharma AB's Price Target?

    The price target for Hansa Biopharma AB over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is HNSBF A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Hansa Biopharma AB is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of HNSBF?

    You can purchase shares of Hansa Biopharma AB via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Hansa Biopharma AB shares.

  • What Is The Hansa Biopharma AB Share Price Today?

    Hansa Biopharma AB was last trading at $3.00 per share. This represents the most recent stock quote for Hansa Biopharma AB. Yesterday, Hansa Biopharma AB closed at $3.00 per share.

  • How To Buy Hansa Biopharma AB Stock Online?

    In order to purchase Hansa Biopharma AB stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

3 High Dividend Dow Jones Stocks
3 High Dividend Dow Jones Stocks

Thanks to surging stock prices over the past two years,…

Will American Tower Stock Recover?
Will American Tower Stock Recover?

The performance of the real estate investment trust, or REIT,…

Will Booking Holdings Stock Split?
Will Booking Holdings Stock Split?

Booking Holdings, the travel and technology company that owns brands…

Stock Ideas

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
59
Is NVDA Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 125x

Sell
46
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
50
NARI alert for Jan 7

Inari Medical [NARI] is up 30.64% over the past day.

Buy
70
PDEX alert for Jan 7

Pro-Dex [PDEX] is up 22.41% over the past day.

Buy
52
ALCO alert for Jan 7

Alico [ALCO] is up 18.99% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock